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Dual effects of angiotensin H on the plasminogen/plasmin system in rat
mesangial cells. Previous studies indicate that angiotensin H (Ang II)
stimulates extracellular matrix synthesis through induction of transform-
ing growth factor-/3 (TGF-13) expression. Here we investigate Ang II
effects on the plasmin protease system. Plasmin both degrades extracel-
lular matrix itself and activates metalloproteinases which then degrade
collagens. Plasmin production is determined by the balance between
plasminogen activators (PA) and their inhibitors (PAI-1,2). The data
presented here indicate that Ang II treatment of mesangial cells in culture
markedly increases PAl-i gene transcription and PAl-i mRNA levels but
does not change the half life of PAl-I mRNA. Increased PAT-i protein
was detected 24 hours after Ang II stimulation with a concomitant
decrease of PA activity. To determine whether these effects were mediated
by TGF-f3, cells were coincubated with Ang II and neutralizing antibody to
TGF-13. Induction of PAT-I at four hours was not altered but the
prolonged effect of Ang II on PAT-i protein synthesis was markedly
diminished. Thus, Ang II acts both through rapid, direct transcriptional
up-regulation of the PAL-i gene and through induction of TGF-13,
providing sustained changes in the PAl-i/PA system, which would favor
extracellular matrix accumulation by inhibiting turnover. These data
provide further evidence that Ang II can act as a potent fibrogenic
molecule independent of its effects on blood pressure.
Angiotensin II (Ang II), the major effector molecule of the
renin-angiotensin system (RAS), has been implicated not only in
regulation of glomerular hemodynamics but also in glomerular
growth and sclerosis [1, 2]. Recent studies have suggested that all
of the components of RAS are present within the glomerulus
where they may function locally to produce Aug II [3—6]. Ang II
type I receptor is strongly expressed in mesangial cells 171,
suggesting that locally produced Ang II can act on mesangial cells,
the key producers of extracellular matrix in progressive glomeru-
losclerosis [8].
Studies also suggest that Ang II up-regulates molecules in-
volved in matrix expansion including fibronectin, collagens, pro-
teoglycans and osteopontin [9—121. These findings, combined with
a rapidly expanding literature indicating that Ang II receptor
blockade or inhibition of Ang II synthesis by converting enzyme
inhibitors retards progressive glomeruloscierosis in both animal
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models and in human renal disease [reviewed in 13], have sparked
new interest in the mechanisms involved in Ang IT-induced
extracellular matrix expansion.
At the same time, publications from this and other laboratories
have provided evidence that overproduction of the cytokine
TGF-/3 underlies the progressive expansion of the mesangial
matrix that characterizes glomeruloscierosis in both experimental
models and in humans. The large literature suggesting that
overproduction of TGF-/3 underlies fibrosis in numerous tissues
has recently been reviewed [141. Work from this laboratory using
cultured mesangial cells conclusively linked Ang II, TGF-p and
production of the extracellular matrix proteins biglycan, fibronec-
tin and collagen type I by showing that Mg IT-induced increases
in these matrix proteins were mediated by increased synthesis and
activation of TGF-/3 [15]. More recently, Lovett and colleagues
provided evidence that the hemodynamic changes which occur
after 5/6 nephrectomy initiate a cascade of endothelial injury,
increased angiotensinogen expression, increased TGF-131 expres-
sion, increased matrix protein expression and deposition and
finally the segmental glomerulosclerosis characteristic of this
model of disease [16].
The goal of the current study was to investigate the possible role
of Ang II in enhancing matrix accumulation by inhibiting matrix
turnover. The protease plasmin can degrade a variety of extracel-
lular matrix molecules. Plasmin generation from plasminogen is
highly regulated by the interaction of plasminogen activators (PA)
and their inhibitors, principally plasminogen activator inhibitor-i
(PAL-I). It has recently been shown that plasmin plays a major
role in mcsangial matrix turnover, not only by degrading matrix
itself, but by activating metalloproteinases that degrade collagens
[17]. When TGF-13 is added to normal glomeruli, PA activity is
markedly decreased and PAl-i synthesis is dramatically increased
[18]. The in vivo importance of this was shown when glomeruli
isolated from animals with mesangial proliferative glomerulone--
phritis at the height of TGF-f3 overexpression were shown to have
markedly decreased PA activity, increased PAl-I synthesis and
increased PAl-i deposition into matrix. in vivo administration of
neutralizing antibodies to TGF-/3 blocked the increase in glomer-
ular PAl-i deposition [18].
Recent reports, using cultured brain astrocytes, vascular endo-
thelial cells and vascular smooth muscle cells, indicated that Mg
11 also influences the plasminogen/plasmin system, and prompted
us to ask whether Ang II leads to alterations in PA/PAl-i balance
664
Kagami et al: Ang II induces PA I-I in mesangial cells 665
in cultured mesangial cells and whether these effects are entirely
or partially mediated by TGF-p (19—22]. We now report strong
evidence that Ang II acts both directly and through induction of
TGF-p, to alter the PAT-i/PA system in a manner that should
decrease plasmin generation and degradation of extracellular
matrix.
Methods
Cell culture
Rat mesangial cells were obtained from intact glomeruli of four
to six-week-old Sprague-Dawley rats and characterized according
to published methods [15, 23, 241. Cells were used between
passages 6 and 9 and were maintained in RPMI 1640 medium
(Sigma Chemical Co., St. Louis, MO, USA) supplemented with
18% fetal bovine serum (FBS; Hyclone Laboratory, Logan, UT,
USA), 100 U/mI penicillin, 100 tg/ml streptomycin, 0.1 U/ml
insulin, 25 mivi Hepes buffer at 37°C in a 5% CO2 incubator. At
confluence, cells were made quiescent by a two day incubation in
serum-free RPM! 1640 medium. Cell proliferation and protein
synthesis assays were performed as previously described [15].
Metabolic labeling of cells and immunoprecipitation
Growth arrested cells, grown to confluence in six-well culture
plates (Costar Corp., Cambridge, MA, USA), were incubated in
serum-free medium under a number of test conditions includ-
ing 108 M Ang II, i0 M saralasin (Sigma), neutralizing
rabbit anti-TGF-/3 IgG (R&D System Inc., Minneapolis, MN,
USA) and control IgG (R&D System Inc.). For immunopre-
cipitation, the medium was collected and centrifuged to remove
cell debris. Aliquots (100 gil) of the radiolabeled medium were
diluted with 850 tl of RIPA buffer (25 m Tris-HCI, pH 7.4, 150
mM NaCl, 0.1% SDS, 0.5% Triton-X 100, 0.5% DOC). To remove
non-specific binding, 10 l normal rabbit serum and 50 sl protein
A-Sepharose (Pharmacia LKB Biotechnology Inc., Uppsala, Swe-
den) were added, tubes were incubated and centrifuged. 10 il of
a rabbit antibody to rat PAT-i (American Diagnostica, New York,
NY, USA) was then added to the supernatant and the mixture was
incubated for 16 hours at 4°C. Immune complexes were recovered
by binding to protein A-Sepharose beads (Pharmacia LKB Bio-
technology Inc.). Beads were washed four times with RIPA buffer
and the immunoprecipitates were analyzed by electrophoresis on
4 to 12% SDS-PAGE under reducing condition as described
previously [15].
Substrate gel electrophoresis zymography)
A modification of the method of Granelli-Piperno and Reich
was used [25]. Plasminogen as substrate for PA (0.03 jIM) and
-casein (0.2 mg/mI), as substratc for plasmin after it was gener-
ated, was added to a 12.5% polyacrylamide gel mixture prior to
casting. Samples were not hulled or reduced prior to the analysis.
After electrophoresis the gel was soaked for one hour in 2.5%
Triton X-100 and overnight in 0.1 M glycine buffer, pH 8.9 at 37°C.
Clear zones of lysis, where -cascin had been degraded, were
visualized by staining the gel with Coomassie blue. In order to
distinguish u-PA from i-PA, gels were also run with 1 ms'i
amiloride in the Triton and glycinc buffer. Amiloride inhibits
u-PA hut not t-PA [26]. The samples were also run on gels without
plasminogen to establish that the zones of lysis were attributable
to PA activity.
Northern blot analysis
Mesangial cells were harvested by lysis in guanidine isothiocya-
nate solution. RNA was isolated by the standard technique of
ultracentrifugation of the lysate through a cesium chloride gradi-
ent followed by ethanol precipitation. For Northern analysis,
RNA was denatured and fractionated by electrophoresis through
a 1.2% agarose gel (10 jIg/lane) and transferred to a Hybond
nylon membrane (Amersham Corp., UK). Nucleic acids were
immobilized by UV irradiation (Stratagene, La Jolla, CA, USA).
Membranes were prehybridized with 50% formamide, 10% Den-
hardt's solution, 0.1% SDS, 5 x SSC, and 200 jIg/ml denatured
salmon sperm DNA and hybridized with DNA probes labeled
with 32P-dCTP by random oligonucleotide priming (Boehringer
Mannheim Biochemicals, Indianapolis, IN, USA). The blots were
washed in 2 x SSC, 0.1% SDS at room temperature for 15
minutes and in 0.1 x SSC, 0.1% SDS at 55°C for 30 minutes. In
addition to ethidium bromide staining, autoradiographic signals
obtained with the rat glyceraldehyde 3-phosphate cDNA probe
served as control for equal loading of the gel slots.
Determination of the stability of mRNA
Quiescent mesangial cells in serum-free medium were incu-
bated for four hours with or without 108 M Ang II, after which
actinomycin D (5 jIg/mi) was added and incubations continued for
0, 1, 2, or 3 hours. Total RNA was isolated as described above and
Northern analysis was used to measure changes in PAT-i and
GAPDH mRNA with time.
Nuclear run-on transcription assays
These assays were performed as described previously [271.
Briefly, quiescent mesangial cells were incubated in serum-free
medium, with or without iO— M Ang II for four hours. Nuclei
were isolated and incubated in a reaction buffer containing ATP,
GTP, CTP, and a-32P UTP for 30 minutes at 30°C. The reaction
was terminated by adding RNase-free DNAase. RNA was isolated
and hybridized to 5 g of plasmids, which contain cDNAs for
PAT-i or GAPDH, and was immobilized on nylon membranes.
The plasmid Bluescript SK (p5K; Stratagene, Cloning Systems, La
Jolla, CA, USA) without an insert, was used as a control. The
hybridization was carried out as for Northern hybridization. The
membranes were washed twice at 42°C for five minutes in 1 X
SSC, followed by one 15 minute wash at 65°C in 0.1 X SSC. The
extent of hybridization was quantified by autoradiography and
densitometry (Ultrascan XL; Pharmacia LKB Biotechnology Inc.,
Pleasant Hill, CA, USA).
eDNA probes
DNA probes used were: PAl-I, 3071-bp PstI-HindIIl rat eDNA
fragment of clone PSK PAIS3 [281; TGF-pi, 300-bp EcoRI-
HindIlI murine cDNA fragment of clone MUI5 [291 and a rat
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) eDNA
[30].
Statistical analysis
Results are presented as mean so. A value of P < 0.05 was
used to determine statistical significance (Student's t-test). Trip-
licate wells were analyzed for each experiment, and each experi-
ment was performed independently at least twice.
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Fig. 1. A. Time course of PA/-i mR/VA induction by Ang 11. Quiescent mesangial cells were exposed to 10-6 M Ang TI and total RNA was extracted at
the indicated times. Time point 0 represents the control. Total RNA (10 mg/lane) was analyzed by Northern blot using 32P-labeled rat PAT-i and
GAPDH probes. Results of the densitometric analysis after correction for GAPDH mRNA, arc graphically shown below. B. Dose response of PAT-i
mRNA induction by Ang TT. Quiescent mesangial cells were incubated for four hours with the indicated concentrations of Ang TT. Total RNA was
extracted at the end of incubation, and analyzed by Northern blot with PAT-i and GAPDH probes. No Ang TI was added to control cells (C). C. Saralasin
inhibits induction of PAT-i mRNA by Ang IT. Quiescent mesangial cells were exposed to saralasin (10 M, Sar), Ang TT (10—8 M), and Ang TI (10—8
M) plus saralasin (10—s M) (Ang TT + Sar) for four hours. Total RNA was extracted at the end of the incubation, and analyzed by Northern blot with
PAT-i and GAPDH probes.
Results
Effect of Ang lion PA 1-I mRNA levels
Addition of 10_6 M Ang II markedly induced PAl-i mRNA of
quiescent mesangial cells (Fig. IA). This increase was sustained
for the entire 48 hours of the experiment, but peaked at four
hours with a 5.0-fold increase. The PAl-I mRNA response to Ang
II was dose-dependent between 10-12 and 10 6 M as demon-
strated in Figure lB. Maximal induction of PAl-I mRNA (8.0-
fold increase) was observed at the highest dose of I0 M Alig II.
The effects of Ang II on PAT-I mRNA induction were decreased
by addition of 10 M saralasin, a competitive antagonist of the
Ang II receptor, indicating that the observed Arig II effects are
receptor mediated (Fig. IC). After the time and dose dependency
of Ang 11 effects on PAT-i mRNA were established, the Ang IT
concentration of 10_8 M was used for all further experiments. This
decision was based primarily on the work of Scikaly, Arant and
Seney [311, whose data suggest that the intrarenal fluid of the rat
contains Ang II concentrations of approximately 10_8 M.
Effect of protein synthesis inhibition on Ang li-induced increase in
PA i-I mRNA
To examine whether protein synthesis is required for induction
of PAl-I gene expression by Ang II, PAl-I mRNA levels were
measured in cells treated with cycloheximide (CH) (10 gIml)
alone or in combination with Ang IT (10 M) at 4 and 24 hours.
This concentration of CH effectively inhibited protein synthesis
(> 92%) as measured by incorporation of 35S-methionine (data
not shown). As seen in Figure 2, at four hours 108 M Ang 11
dramatically increased PAl-i mRNA levels. However, CH also
increased message levels to the same extent in the absence of Ang
IT, probably because CH inhibits the synthesis of a protein
required for degradation of PAl-I mRNA. When both CH and
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Fig. 2. Effect of cycloheximide on the induction of PA I-i mRNA byAng II.
Quiescent mesangial cells were treated with iO— M Ang II and/or CH (10
g/ml) for four hours and for 24 hours. Total RNA was extracted at the
end of the incubation, and analyzed by Northern blot with PAT-i and
GAPDH probes.
Fig. 3. Effects of Ang II on PAl-i gene transcription. Quiescent mesangial
cells were treated with or without 10—8 M Ang II for four hours. Nuclei
were isolated and 32P-labeled transcription products were hybridized to
linearized denatured DNA of rat PAT-i, vector plasmid (pSK), and
GAPDH.
Ang II are added together, the increase is approximately the sum
of either CH or Ang II alone (7.8-fold vs. 4-fold and 4.1-fold for
Ang II and CH alone, respectively). This strongly suggests that the
rapid induction of PAl-I gene by Ang II seen at four hours does
not require de novo protein synthesis. A different situation exists
after 24 hours when Ang II alone resulted in a 2.9-fold increase in
PAl-i message, CH alone an increase of 1.9-fold. However, when
both are added, the PAl-I message increase was the same as with
cyclohexamide alone or 1.9-fold. Thus, the 24 hours data suggest
that sustaining the Ang 11-induced increase in PM-i mRNA for
24 hours does require new protein synthesis.
Effect of Ang II on PAl-i gene transcription rate and mRNA
turnover
To determine the relative importance of transcriptional and
post-transcriptional mechanisms in the accumulation of PAl-i
Fig. 4. Effects of Ang II on PAl-i mRNA degradation rate. Quiescent
mesangial cells were treated with or without 108 M Ang II for four hours
and then exposed to actinomycin D (5 mglml). Total RNA was harvested
at the indicated times thereafter and subjected to Northern blot analysis
with PAl-i and GAPDH probes (A). B. The results are graphed as the
percent of mRNA remaining (normalized to GAPDH) for either control
cells (0) or those exposed to Ang II (•). Each point represents the
mean SD of values obtained from two separate experiments. t112 was
calculated by interpolation at 50%.
mRNA following Ang II treatment, we examined the effect of Ang
II on PAl-i gene transcription and mRNA degradation (Figs. 3
and 4). Nuclear transcription run on assays were performed to
determine the rate of the PAl-i gene transcription. Four hours
after treatment with 108 M Ang II, PAl-i gene transcription had
increased fourfold, as compared to the basal, control rate (Fig. 3).
There were minimal levels of hybridization to plasmid alone
(pSK) and there was no significant difference in signal intensity
between nuclear transcripts from control and Ang II exposed cells
when these were hybridized to a GAPDH eDNA.
The disappearance of PAl-I mRNA in control and Ang II
treated cells was assayed by actinomycin D chase experiments.
Mesangial cells were treated with or without 10-8 M Ang II for
four hours and then exposed to actinomycin D to arrest new RNA
synthesis. Total RNA was harvested at 0, 1, 2 and 3 hours after
actinomycin D inoculation. As shown by Northern blot in Figure
4A and in graphical form in Figure 4B, PAl-i mRNA declined
with an apparent half life (t112) of 1.55 hours in control cells and
1.34 hours in Ang II treated cells. The data presented in Figures
3 and 4 strongly suggest that Ang II increases the rate of PAl-I
gene transcription but does not affect PAl-i mRNA stability.
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Effect of Ang II on PAl-i protein synthesis by mesangial cells
Equal amounts of 35S-methionine-labeled conditioned medium
were immunoprecipitated with specific antibody to rat PAT-i.
3H-thymidine incorporation did not differ between Ang Il-treated
and control cultures, indicating that this represented medium
from an equal number of cells. Incubation of mesangial cells with
10—8 M Ang II for 24 hours resulted in a fourfold increase in newly
synthesized PAl-i protein immunoprecipitated from the culture
supernatant (Fig. 5). While saralasin had no effect on PAl-i
immunoprecipitated from control cultures, i0 M saralasin mark-
edly reduced Ang 11-stimulated synthesis of PAl-I protein to
control levels.
Effect of TGF-/3 neutralizing antibody on Ang 11-induced PAl-i
mRNA and protein
To study whether the effect of Ang II on PAl-i gene induction
is mediated by Ang IT-induced increases in TGF-f3 activity, Ang II
treated mesangial cells were coincubated with TGF-p neutralizing
antibody (100 jxglml) or control lgG (100 jxglml). As reported
previously [15], this concentration of neutralizing antibody com-
pletely blocks Ang Il-induced increases in TGF-J3 activity. Addi-
tion of neutralizing antibody to TGF-/3 had no effect on the large
increase in PAl-i mRNA seen at four hours (Fig. 6). However,
PAl-I gene expression was reduced somewhat at eight hours and
was significantly reduced by two-thirds by TGF-/3 antibody at 24
hours. As we reported earlier, TGF- transcript levels, also shown
in Figure 6, were increased by Ang IT at four hours and persisted
until 24 hours [15]. Consistent with the results shown in Figure 2,
where protein synthesis was blocked by addition of cycloheximide,
these results suggest that early induction of PAl-i gene expression
by Ang II is independent of Ang IT-induced increases in TGF-[3
expression. However, prolonged elevation of PAT-I mRNA ap-
pears to be significantly mediated by Ang Il-induced increases in
TGF-f3. This TGF-/3-mediated effect on PAl-I gene expression
was confirmed by immunoprecipitation of newly synthesized
PAT-i protein as shown in Figure 7. Coincubation of mesangial
cells with 10 M Ang II and TGF- antibody for 24 hours
significantly reduced, again by two-thirds, the stimulatory effect of
Ang lion PAT-i protein synthesis. Coincubation of Ang TI-treated
cells with normal rabbit IgG had no effect on stimulated PAl-i
protein synthesis.
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Fig. 6. Effect of coincubation of Ang II and neutralizing antibody to TGF-p
antibody on the gene expression of PA I-i and TGF-ii A. Quiescent
mesangial cells were treated with or without iO M Ang TI in the presence
of anti-TGF- antibody or control IgG. Total RNA was harvested at the
indicated times and subjected to Northern blot analysis with PAl-i,
TGF-p and GAPDH probes. B and C. Graphs of the mean SD of two
experiments were made after densitometry and correction for GAPDH
and are shown graphically below. Lane 1, control + control antibody;
Lane 2, control + TGF-/3 antibody; Lane 3, Ang II + control antibody;
Lane 4, Ang II + TGF-f3 antibody.
Effects of Ang II and TGF-13 antibody on PA activity
To evaluate the effect of Ang TI on the PA activity of cultured
mesangial cells, we performed zymographic analysis of conversion
of plasminogen to plasmin by PA present in culture supernatants
from cells stimulated with or without i0 M Ang II. Samples
loaded Onto SDS-polyacrylamide gels containing plasminogen and
a-casein produced two zones of lysis indicative of PAs (Fig. 8,
A—), Amiloride, a known inhibitor of u-PA catalytic activity,
specifically inhibited appearance of the lower band (Fig. 8, A+)
1261. Thus, as demonstrated in other rat cell cultures [32, 33], the
upper band (60 kDa) probably corresponds to t-PA and lower
band (40 kDa) most likely represents u-PA. Exposure of mesan-
gial cells to 10 M Ang Ii for 24 hours decreased both bands of
PA activity as compared with control culture (lanes 1, 2). The role
of the Ang Il-induced increases in TGF-/3 production in these
effects was also examined. While addition of control TgG to Ang
TI-treated cultures had no effect on decreased PA activity, TGF-f3
antibody reversed the Ang Il-induced decrease in PA activity to
normal control levels (lanes 5, 6). No obvious effect on PA activity
was observed in control cultures treated with either control IgG or
anti-TGF-p antibody (lanes 3, 4). These results suggest that the
Ang Il-induced decrease in PA activity is mediated by Ang
—45
Fig. 5. Effect of Ang II on mesangiat cell synthesis of PA 1-1 protein.
Mesangial cell cultures incubated with saralasin alone (10- M, Sar), Ang
II (l0 M), or Ang IT (10—s M) plus saralasin (l0 M, Ang IT + Sar) were
radiolabeled with 35S-methionine. Culture supernataots were used for
immunopreeipitation of PAl-i protein.
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Fig. 7. Ejfrct of coincubation of Ang II and neutralizing antibody to TGF-p
on PAl- 1 protein synthesis. A. Mesangial cell cultures incubated with or
without io- M Ang II in the presence of TGF-13 antibody or control IgG
were radiolabeled with 35S-methionine under conditions described in
Methods. Culture supernatants were used for immunoprecipitation of
PAT-i protein. B. Densitometry data are plotted below. Treatments are: 1,
control + control antibody; 2, control + TGF-f3 antibody; 3, Ang II +
control antibody; 4, Ang H + TGF-p antibody.
TI-induced increases in TGF-/3 activity. No bands were seen when
plasminogen was omitted from the gel.
Discussion
For many years Ang II has been implicated in pathological
matrix accumulation in both experimental models of glomerulo-
sclerosis and in chronic human renal disease primarily because of
numerous studies showing decreased sclerosis resulting from Ang
II blockade. Recent evidence supports the idea that local activa-
tion of the RAS may contribute to glomerulosclerosis, indepen-
dent of circulating RAS [34—36]. Indeed, studies using double
transfection of renin and angiotensinogen genes into rat glomeruli
demonstrated that glomerular activation of the RAS results in
mesangial cell activation and mesangial matrix accumulation [37].
The mechanism of Ang Ii's fibrogenic effects have, however,
remained unclear until recently. Now a body of data strongly
suggests that Ang Ii is fibrogenic through induction of TO F-p.
These data include studies implicating overexpression of TGF-13
as a key determinant in tissues fibrosis [14], those showing that
Ang U up-regulates TGF-f3 [38] and one indicating that Ang
Fig. 8. Zy,'nographic analysis of the effect of coincubation of Ang II and
neutralizing antibody to TGF- 13 on PA activity of mesangial cell cultures.
Quiescent mesangial cells were treated with or without 10 M Ang II in
the presence of TGF-f3 antibody or control IgG for 24 hours, and then
culture supernatants were analyzed by SDS-PAGE and zymography, in the
absence (A—) or in the presence (A+) of 1 mM amiloride.
Il-induced increases in matrix protein synthesis are mediated by
TGF-f3 [151. Also, infusion of Ang II into rats with mini osmotic
pumps for one week leads to marked increases in glomerular
mRNA for TGF-p and collagen type 1 [15]. Conversely, Ang II
blockade has now been shown to dramatically reduce TGF-p
overexpression in both humans with IgA nephropathy [39] and in
a number of animal models of fibrotic renal disease [40—47].
Many reports have shown that TGF-p also decreases synthesis
of plasminogen activators u-PA and t-PA, which convert plasmin-
ogen to plasmin and dramatically increases synthesis of the PA
inhibitor PAl-i [48—501. The net effect is decreased plasmin
generation. Plasmin not only degrades matrix molecules fibronec-
tin, laminin, and vitronectin, but also stimulates conversion of
procollagenases to the collagenases that are required for collagen
degradation. That this system is involved in extracellular matrix
degradation in the kidney was suggested by studies where degra-
dation of matrix by human mesangial cells in culture was reduced
by addition of antibodies to either u-PA or t-PA, but increased by
addition of antibodies to PAl-i [17]. Disruption of u-PA genes in
knockout mice specifically abolishes breakdown of extracellular
matrix by cells [511. Also supporting this role for plasmin is a
recent study using genetically altered mice that either overex-
pressed or were completely deficient in PAL-I. Induction of
pulmonary fibrosis with bleomycin resulted in normal lung colla-
gen content in PAl-i-deficient mice and increased collagen con-
tent in the PAl-I overexpressing mice [52]. In experimental
models of glomeruionephritis in the rat, increases in PAT-I
expression and decreases in PA closely correlate with glomerular
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matrix accumulation [18, 53, Finally, a number of recent
studies have shown increased PAT-i staining in human glomeru-
loscierosis [55—57].
Reports that Ang II increases PAl-i expression [19—22]
prompted us to investigate Ang II effects on the plasmin protease
system in cultured rat mesangial cells. We found that Ang II
markedly enhanced PAl-i production in cultured rat mesangial
cells at the level of mRNA, protein, and turned the net balance of
PAl-i/PA toward inhibition of plasmin generation. The dose-
response characteristics and sensitivity to saralasin of the PAT-i
induction are entirely consistent with these being Ang II receptor-
mediated events. After 24 hours approximately two-thirds of this
effect is mediated by autocrine TGF-f3.
The increase of PAl-i mRNA by Ang II is rapid, peaking at
four hours. Nuclear run on assays and mRNA stability experi-
ments using actinomycin D after stimulation with Ang 11 for four
hours indicate that the effect of Ang Ii is primarily to increase
transcription of PAl-i gene. The rapid induction of PAl-I gene
independent of endogenous TGF-J3 production and the lack of
inhibition by cycloheximide suggests that Ang II acts directly on
the PAl-i gene through mechanisms independent of de novo
protein synthesis.
On the other hand, the finding that sustained increases in PAT-i
expression require de novo protein synthesis and are significantly
mediated by endogenous TGF-j3 production suggests that mech-
anisms for activation of PAT-i gene at this time point are different
from those at early time points. This prolonged stimulatory effect
on PAT-i synthesis is similar to our published data showing that
Ang II induced increases in extracellular matrix protein synthesis
are mediated through enhanced synthesis and bioactivation of
TGF-13 [15]. The direct and indirect actions of Ang II to increase
PAl-i are reminiscent of Ang II's direct and indirect role in
maintaining homeostasis of systemic blood pressure. In hypoten-
sive states, Ang II acts immediately and directly to increase blood
pressure through its vasoconstrictive properties. Simultaneously,
Ang II induces a long-term, indirect effect to increase blood
pressure by stimulating the release of aldosterone, which increases
sodium reabsorption thereby raising intravascular volume. It is
interesting to view Ang II as having similar homeostatic actions on
maintenance of the extracellular matrix. Immediately following
tissue injury fibrin is deposited into the wound. By rapidly
increasing expression of PAl-I, Ang II may act to inhibit plasmin
generation and fibrinolysis, thereby stabilizing the temporary
fibrin matrix. This matrix is subsequently replaced by a permanent
matrix through Ang H's indirect action to induce TGF-/3, which in
turn increases matrix protein synthesis and sustained expression
of PAl-I. Thus, in both the maintenance of blood pressure and
extracellular matrix, Ang II has immediate and direct as well as
delayed, indirect actions.
In summary, our results show that Ang II decreases PA activity
by cultured mesangial cells, cells where the plasminogen/plasmin
protease system has been shown to be key to matrix turnover [17].
This study goes beyond previous studies by demonstrating both
rapid, direct, TGF-f3-independent effects and prolonged, TGF-/3-
dependent effects that together would be expected to provide
sustained decreases in plasmin generation, favoring extracellular
matrix accumulation by inhibiting turnover. The data further
provide additional evidence that Ang TI, through its induction of
PAl-i and TGF-13, can act as a potent fibrogenic molecule
independent of its effects on blood pressure.
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Appendix
Abbreviations are: Ang II, angiotensin II; PA, plasminogen activator;
PAl-i, plasminogen activator inhibitor, type 1; RAS, renin-angiotensin
system; (25 msi Tris-HCI, pH 7.4, 150 mM NaCI, 0.1% SDS, 0.5% Triton-X
100, 0.5% DOC,) RIPA buffer; GAPDH, glyceraldehyde-3-phosphate
dehydrogenase; u-PA, urokinase; t-PA, tissue plasminogen activator; Sar,
saralasin; CH, cycloheximidc; pSK, plasmid Bluescript SK.
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